Acies bio
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|---|---|
Revenues | 1.1m | 1.3m | 1.9m | 2.2m | 2.5m | 2.4m |
% growth | - | 23 % | 38 % | 19 % | 14 % | (3 %) |
EBITDA | <1m | <1m | <1m | <1m | <1m | <1m |
% EBITDA margin | 25 % | 9 % | 11 % | 11 % | 10 % | 8 % |
Profit | <1m | (<1m) | <1m | <1m | <1m | <1m |
% profit margin | 10 % | (5 %) | 30 % | 4 % | 1 % | - |
R&D budget | - | - | - | - | - | 2.0m |
R&D % of revenue | - | - | - | - | - | 82 % |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
€50.0k | Grant | ||
N/A | €1.8m | Grant | |
N/A | - | ||
Total Funding | AUD3.1m |
Related Content
Recent News about Acies bio
EditACIES BIO is a biotechnology contract research organization offering state-of-the-art R&D services to pharmaceutical, chemical, biotech and food industries. We provide full support from idea conceptualization through research to product development. Combining biotechnology and synthetic organic chemistry expertise, we offer a comprehensive service, covering all key development steps for efficient production of biosynthetic natural products or their semi-synthetic derivatives, as well as entirely synthetic compounds.
Working with some of the largest international companies, we provide to our clients full R&D support both in our laboratories as well as on-site at the client’s facilities.
With experience and know-how in natural product (bio)synthesis, milestone-based approach to projects, innovativeness and flexibility, as well as competitive pricing, ACIES BIO aims to become the premier partner in R&D outsourcing for pharmaceutical companies.